Genmab A/S (GMAB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Genmab A/S, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Genmab A/S (GMAB) has returned -12.89% so far this year and 37.03% over the past 12 months. Over the last ten years, GMAB has returned 6.68% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jun 1, 2009, GMAB's average daily return is +0.09%, while the average monthly return is +1.82%. At this rate, your investment would double in approximately 3.2 years.

Historically, 50% of months were positive and 50% were negative. The best month was Jul 2012 with a return of +56.0%, while the worst month was Aug 2011 at -51.6%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 6 months.

On a daily basis, GMAB closed higher 37% of trading days. The best single day was Jul 24, 2012 with a return of +57.5%, while the worst single day was Aug 8, 2011 at -51.6%.

Genmab A/S has an annualized alpha of 14.46%, beta of 0.66, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since June 02, 2009.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (91.81%) than losses (88.68%) — typical of diversified or defensive assets.
• Beta of 0.66 may look defensive, but with R² of 0.07 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GMAB ranks 69 for risk / return — better than 69% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Genmab A/S (GMAB) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Genmab A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Genmab A/S was 84.20%, occurring on Aug 8, 2011. Recovery took 538 trading sessions.

The current Genmab A/S drawdown is 44.93%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Genmab A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Genmab A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.